Nuvectis Pharma Inc (NVCT) Stock Price, Quote & News

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 614 3150

Website: www.nuvectis.com

Address:

1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, United States

topstockalerts Jun. 24 at 9:37 PM

Top Gainers PT2 $STFS $CUPR $NVCT $BOXL $ABSI

0 · Reply

UNLV Jun. 24 at 8:27 PM

$NVCT below, Nuvectis pays 20M upfront. Believing NXP900 likely multi-billion tempered concerns somewhat around dilution

0 · Reply

SahreIn Jun. 24 at 8:19 PM

$NVCT damn the drug is not even approved yet …. Will fall big soon

2 · Reply

Zipcash Jun. 24 at 7:23 PM

$NVCT Has anyone confirmed this isn’t a pump and dump news ? With Chinese stocks, one always needs to make sure to not get scammed?!!!

1 · Reply

prismmarketview Jun. 24 at 7:08 PM

$NVCT just inked an ex‑China license with China’s Haisco (002653) for two clinical‑stage drugs: NXP200 (BRAF paradox‑breaker) and NXP100 (once‑daily complement Factor B inhibitor). #NVCT #Haisco #biotech https://x.com/PrismMarketView/status/2069860040765255952?s=20

0 · Reply

ShadowNick Jun. 24 at 6:16 PM

$NVCT give us 30$

1 · Reply

BenGang Jun. 24 at 6:12 PM

$SPCX $ABSI $NVCT

0 · Reply

topstockalerts Jun. 24 at 6:08 PM

Top Gainers PT2 $ABSI $STFS $CUPR $ICCM $NVCT

0 · Reply

johnnygogogo Jun. 24 at 5:21 PM

$NVCT the upfront payment is more cash than the company currently has. Obviously tapping an ATM right now or going to announce a secondary after the close. Not a bad thing, but the math ain’t mathing otherwise.

1 · Reply

topstockalerts Jun. 24 at 5:04 PM

Top Gainers PT2 $ICCM $VTAK $ABSI $SKYQ $NVCT

0 · Reply

Nuvectis Pharma price target raised to $22 from $18 at Lucid Capital

2026-06-22T15:06:27.000Z - 2 days ago

Nuvectis Pharma price target raised to $39 from $13 at H.C. Wainwright

Jun 22, 2026, 8:34 AM EDT - 2 days ago

Nuvectis gains two experimental drugs in licensing deal with China's Haisco

Jun 22, 2026, 8:30 AM EDT - 2 days ago

Nuvectis Pharma Transcript: Status update

Jun 22, 2026, 8:30 AM EDT - 2 days ago

Nuvectis Pharma Press release: Status update

2026-06-22T12:01:43.000Z - 2 days ago

Nuvectis Pharma announces license agreement with Haisco for two compounds

Jun 22, 2026, 7:30 AM EDT - 2 days ago

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

2026-06-12T16:12:33.000Z - 12 days ago

Nuvectis Pharma price target raised to $13 from $10 at H.C. Wainwright

Jun 11, 2026, 10:00 AM EDT - 13 days ago

Nuvectis Pharma Transcript: AGM 2026

May 19, 2026, 9:00 AM EDT - 5 weeks ago

Nuvectis Pharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 14, 2026, 7:30 AM EDT - 5 weeks ago

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

May 11, 2026, 7:00 AM EDT - 6 weeks ago

Nuvectis Pharma Slides: Corporate presentation

May 5, 2026, 7:30 AM EDT - 7 weeks ago

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

May 5, 2026, 7:30 AM EDT - 7 weeks ago

Nuvectis Pharma Earnings release: Q1 2026

May 5, 2026, 7:30 AM EDT - 7 weeks ago

Nuvectis Pharma Quarterly report: Q1 2026

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Nuvectis Pharma Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Nuvectis Pharma Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

2026-03-19T19:35:17.000Z - 3 months ago

Nuvectis Pharma management to meet with Maxim

Mar 13, 2026, 7:00 AM EDT - 3 months ago

Nuvectis Pharma Slides: Corporate presentation

2026-02-13T21:05:11.000Z - 4 months ago

Nuvectis Pharma files $150M mixed securities shelf

Feb 13, 2026, 7:00 AM EST - 4 months ago

Nuvectis Pharma Registration statement: Registration Filing

Feb 11, 2026, 7:30 AM EST - 4 months ago

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Feb 11, 2026, 7:00 AM EST - 4 months ago

Nuvectis Pharma Earnings release: Q4 2025

Feb 11, 2026, 7:00 AM EST - 4 months ago

Nuvectis Pharma Annual report: Q4 2025

2025-12-17T12:13:26.000Z - 6 months ago

Nuvectis Pharma announces initiation of Phase 1b study of NXP900

Dec 17, 2025, 7:00 AM EST - 6 months ago

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Dec 2, 2025, 8:00 AM EST - 7 months ago

Nuvectis Pharma Transcript: KOL Event

Dec 2, 2025, 8:00 AM EST - 7 months ago

Nuvectis Pharma Slides: KOL Event

Nov 25, 2025, 8:00 AM EST - 7 months ago

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Nov 4, 2025, 4:00 PM EST - 8 months ago

Nuvectis Pharma Earnings release: Q3 2025

Nov 4, 2025, 4:00 PM EST - 8 months ago

Nuvectis Pharma Quarterly report: Q3 2025

2025-11-04T13:20:44.000Z - 8 months ago

Nuvectis Pharma reports Q3 EPS (44c), consensus (25c)

Nov 4, 2025, 8:15 AM EST - 8 months ago

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

2025-11-04T12:36:25.000Z - 8 months ago

Nuvectis Pharma reports Q3 net loss $7.5M vs $4.2M last year

2025-10-27T12:17:17.000Z - 8 months ago

Nuvectis Pharma provides highlights from NXP900 poster presentations

Oct 16, 2025, 8:00 AM EDT - 8 months ago

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-09-25T12:05:11.000Z - 9 months ago

Nuvectis Pharma appoints Juan Sanchez to board of directors

Sep 5, 2025, 7:00 AM EDT - 10 months ago

Nuvectis Pharma Slides: Corporate Presentation

Sep 4, 2025, 7:30 AM EDT - 10 months ago

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 8:30 AM EDT - 11 months ago

Nuvectis Pharma Transcript: Status Update

Aug 12, 2025, 8:30 AM EDT - 11 months ago

Nuvectis Pharma Press release: Status Update

2025-08-11T21:10:25.000Z - 11 months ago

Nuvectis Pharma initiates NXP900 program

Aug 11, 2025, 4:30 PM EDT - 11 months ago

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

Aug 5, 2025, 9:00 AM EDT - 11 months ago

Nuvectis Pharma Quarterly report: Q2 2025

Aug 5, 2025, 9:00 AM EDT - 11 months ago

Nuvectis Pharma Earnings release: Q2 2025

2025-08-05T11:35:18.000Z - 11 months ago

Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year

Aug 5, 2025, 7:30 AM EDT - 11 months ago

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

2025-08-04T14:01:05.000Z - 11 months ago

Nuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright

2025-07-31T11:50:58.000Z - 11 months ago

Nuvectis Pharma provides final clinical data update from NXP800 Phase 1b study

Jul 31, 2025, 7:45 AM EDT - 11 months ago

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

2025-07-08T12:15:12.000Z - 1 year ago

Nuvectis Pharma’s NXP900 shows positive drug interaction results in lung cancer

Jun 13, 2025, 11:00 AM EDT - 1 year ago

Nuvectis Pharma Slides: Corporate Presentation

May 20, 2025, 10:30 AM EDT - 1 year ago

Nuvectis Pharma Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 16, 2025, 4:35 PM EDT - 1 year ago

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

May 6, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Earnings release: Q1 2025

2025-05-06T12:17:22.000Z - 1 year ago

Nuvectis Pharma reports Q1 EPS (27c) vs (25c) last year

May 6, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

2025-04-30T10:12:04.000Z - 1 year ago

Nuvectis Pharma price target raised to $15 from $11 at H.C. Wainwright

Apr 29, 2025, 4:25 PM EDT - 1 year ago

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Proxy statement: Proxy Filing

2025-04-02T11:45:09.000Z - 1 year ago

Nuvectis Pharma initiated with a Buy at Maxim

2025-03-17T07:30:05.000Z - 1 year ago

Nuvectis Pharma initiated with a Buy at Laidlaw

Mar 14, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Feb 25, 2025, 9:30 AM EST - 1 year ago

Nuvectis Pharma Annual report: Q4 2024

Feb 25, 2025, 9:30 AM EST - 1 year ago

Nuvectis Pharma Earnings release: Q4 2024

Feb 7, 2025, 8:30 AM EST - 1 year ago

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Feb 5, 2025, 9:01 AM EST - 1 year ago

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Feb 4, 2025, 4:05 PM EST - 1 year ago

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma Quarterly report: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma Earnings release: Q3 2024

Oct 28, 2024, 8:21 AM EDT - 1 year ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

DRUG

Sep 9, 2024, 12:00 PM EDT - 1 year ago

Nuvectis Pharma Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Aug 6, 2024, 8:45 AM EDT - 2 years ago

Nuvectis Pharma Quarterly report: Q2 2024

Aug 6, 2024, 8:45 AM EDT - 2 years ago

Nuvectis Pharma Earnings release: Q2 2024

Aug 6, 2024, 8:28 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

May 16, 2024, 8:30 AM EDT - 2 years ago

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

May 7, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

May 7, 2024, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Earnings release: Q1 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Slides: Corporate Presentation

Apr 8, 2024, 8:30 AM EDT - 2 years ago

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Mar 15, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 14, 2024, 9:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Mar 5, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Mar 5, 2024, 7:00 AM EST - 2 years ago

Nuvectis Pharma Earnings release: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Nuvectis Pharma Annual report: Q4 2023

Feb 9, 2024, 8:32 AM EST - 2 years ago

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Feb 9, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Jan 3, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 8, 2023, 7:00 AM EST - 2 years ago

Nuvectis Pharma Quarterly report: Q3 2023

Nov 8, 2023, 7:00 AM EST - 2 years ago

Nuvectis Pharma Earnings release: Q3 2023

Sep 25, 2023, 7:30 PM EDT - 2 years ago

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Sep 14, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Transcript: Status Update

Sep 6, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Aug 17, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Aug 9, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Quarterly report: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Earnings release: Q2 2023

May 15, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 10, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

May 10, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Quarterly report: Q1 2023

May 10, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Earnings release: Q1 2023

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 27, 2023, 10:14 AM EDT - 3 years ago

Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 10, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

Mar 17, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

Mar 17, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Registration statement: Registration Filing

Mar 10, 2023, 8:00 AM EST - 3 years ago

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

Mar 7, 2023, 8:00 AM EST - 3 years ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

topstockalerts Jun. 24 at 9:37 PM

Top Gainers PT2 $STFS $CUPR $NVCT $BOXL $ABSI

0 · Reply

UNLV Jun. 24 at 8:27 PM

$NVCT below, Nuvectis pays 20M upfront. Believing NXP900 likely multi-billion tempered concerns somewhat around dilution

0 · Reply

SahreIn Jun. 24 at 8:19 PM

$NVCT damn the drug is not even approved yet …. Will fall big soon

2 · Reply

Zipcash Jun. 24 at 7:23 PM

$NVCT Has anyone confirmed this isn’t a pump and dump news ? With Chinese stocks, one always needs to make sure to not get scammed?!!!

1 · Reply

prismmarketview Jun. 24 at 7:08 PM

0 · Reply

ShadowNick Jun. 24 at 6:16 PM

$NVCT give us 30$

1 · Reply

BenGang Jun. 24 at 6:12 PM

$SPCX $ABSI $NVCT

0 · Reply

topstockalerts Jun. 24 at 6:08 PM

Top Gainers PT2 $ABSI $STFS $CUPR $ICCM $NVCT

0 · Reply

johnnygogogo Jun. 24 at 5:21 PM

1 · Reply

topstockalerts Jun. 24 at 5:04 PM

Top Gainers PT2 $ICCM $VTAK $ABSI $SKYQ $NVCT

0 · Reply

Powell6531 Jun. 24 at 4:26 PM

$ABSI $FMFC $GALT $LIFE $NVCT 👀✔️

0 · Reply

Stock_Catcher Jun. 24 at 4:26 PM

$FMFC Woww $GALT $ABSI $NVCT $LIFE Clean Uptrends all day

0 · Reply

prismmarketview Jun. 24 at 4:25 PM

PRISM Mid-Day Movers: MedTech and New Energy are Today’s Leaders. IceCure Medical Ltd. (NASDAQ: $ICCM ) is surging again today, with the stock up about 44% to 8.84 from a prior close of 6.12. Sky Quarry Inc. (NASDAQ: $SKYQ ) is having a big momentum day, with the stock up about 36% to 2.23 from a prior close of 1.64. Other Notable Movers: Nuvectis Pharma ( $NVCT ) up 27% Definium Therapeutics ( $DFTX) up 22% Sangamo Therapeutics ( $SGMO) down -58% https://prismmarketview.com/prism-mid-day-movers-medtech-and-new-energy-are-todays-leaders/

0 · Reply

UNLV Jun. 24 at 4:12 PM

$NVCT Strong opinion here - licensing deal likely happened with China firm Haisco having inside track marketing Nuvectis mono therapies in Asia Big market potential as Asians are much more likely to have EGFR mutations that NXP900 targets

0 · Reply

Merlintrader Jun. 24 at 3:40 PM

$ABSI Biotech Radar – $DFTX $ABSI $NVCT – June 24, 2026 https://www.merlintrader.com/biotech-radar-june24-dftx-absi-nvct/

0 · Reply

MaverikIT Jun. 24 at 3:39 PM

@Jblack500 @BustaCapital @No_Face_character @WAJeff @cynicaloptimist @IsabellaDC $NVCT - nice

1 · Reply

kkorotney Jun. 24 at 3:17 PM

$NVCT Great Day today. Over the last couple years I was watching the S&P rip, while my money was parked here. Glad to finally see my patience and conviction starting to pay off. LFG!

0 · Reply

prohibited Jun. 24 at 2:49 PM

$NVCT breaking it’s own record

0 · Reply

UNLV Jun. 24 at 2:27 PM

$NVCT glad I didn’t wait on data… 100x parlay - NVCT x ? There’ll be more opportunities to track insiders

1 · Reply

buyandsold Jun. 24 at 1:57 PM

$NVCT The shareholder base was all waiting for NXP900 data. That's still the case after the in-licensing agreement. For people looking to build a position after the in-licensing announcement, it's very challenging because there are few sellers.

1 · Reply

sammythecat Jun. 23 at 11:07 PM

$NVCT Breakout baby!

0 · Reply

essiepaul Jun. 23 at 9:49 PM

$NVCT Bet u Charles is a happy man! Well deserved to RB too!

1 · Reply

Market Cap	465.53M
Revenue (ttm)	0.00
Net Income (ttm)	-26.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,282,300
Avg Vol	130,836
Day's Range	N/A - N/A
Shares Out	26.53M
Stochastic %K	98%
Beta	-0.07
Analysts	Strong Sell
Price Target	$17.00